CRTSF - Novonesis: A New Beginning For Novozymes And Christian Hansen

2024-03-06 01:43:24 ET

Summary

• Novozymes reported its last annual results for fiscal 2023 with revenue growing, but bottom line declining.
• Novonesis is the new company generated by the merger between Novozymes and Christian Hansen.
• The stock is trading above intrinsic value once again and is not the best investment anymore.

In October 2023, I published my last article about Novozymes A/S ( OTCPK:NVZMF ) – and it was my first article about the stock in which I was rather bullish. And although the stock was trading slightly below my calculated intrinsic value, and I rated the stock as a “Buy” I did not purchase any shares myself as I assumed that the stock might decline a little bit lower. My preferred entry point was DKK 250....

For further details see: